Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT00572481

Axillary Reverse Mapping

ARM: Axillary Reverse Mapping, A Prospective Study

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
1,000 (estimated)
Sponsor
University of Arkansas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

We hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a SLNB and / or ALND. Therefore, mapping the drainage of the arm during the procedure would decrease the likelihood of inadvertent disruption of the lymphatics and the subsequent development of lymphedema. A combination of radioactivity and blue dye will be used.

Detailed description

Mapping Procedure: Each patient will receive an injection of 1.0 mCi of technetium-99m sulfur colloid into the normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. If the radioactive SLN cannot be located prior to incision via gamma probe then the blue dye will be used in the breast either in the subareolar plexus or peritumorally at the discretion of the surgeon. For this contingency (expected to occur \<3% of the time), the blue dye will be used in the breast (and NOT the arm), as the prime concern is locating the SLN for staging. If the blue dye is unnecessary to find the sentinel node draining from the breast, then it will be injected dermally in the upper inner arm along the Biceps groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in either the subareolar plexus, peritumorally (intraparenchymal or dermally), or dermally in the patient's ipsilateral arm dependent upon the contingencies stated above. Site of all injections (radioactivity and/or blue dye) will be recorded.

Conditions

Interventions

TypeNameDescription
PROCEDUREAxillary Reverse MappingDuring surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.

Timeline

Start date
2007-05-01
Primary completion
2026-10-01
Completion
2027-11-01
First posted
2007-12-13
Last updated
2025-11-06

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00572481. Inclusion in this directory is not an endorsement.